Podcast: This Week in Managed Care—CAR T Therapy Coverage and Other Health News

Article

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included CMS' proposal to cover chimeric antigen receptor T-cell therapy; a study faulting the FDA’s handling of fentanyl oversight; and breast surgeons calling for genetic testing for all patients with breast cancer.

You may need to log in to the website to access this podcast.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy

Study Criticizes FDA Safety Oversight of Rapid-Release Fentanyl

Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer

Greater Diet Drink Consumption Heightens Stroke Risk in Postmenopausal Women

Advancing Quality Oncology Care in the Evolving Value-Based Care Landscape

Read more about the stories in this podcast:

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – June 27, 2025

Noah Stansfield
June 27th 2025
Article

Review top news and interview highlights from the week ending June 27, 2025.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio
June 18th 2025
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Around the Helix: Cell and Gene Therapy Company Updates – June 25, 2025

Around the Helix: Cell and Gene Therapy Company Updates – June 25, 2025

Noah Stansfield
June 25th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Linda Marbán, PhD, the CEO of Capricor Therapeutics

FDA Indicates AdComm Not Currently Required for Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel

Noah Stansfield
June 24th 2025
Article

In a mid-cycle review meeting, the agency also noted that the review committee found no major deficiencies with the BLA package.

Zhengzhou Revo-Gene Technology Assesses DC-CTL Cells for the Treatment of Solid Tumors in Real World Exploratory Study

Zhengzhou Revo-Gene Technology Assesses DC-CTL Cells for the Treatment of Solid Tumors in Real World Exploratory Study

Noah Stansfield
June 23rd 2025
Article

The study, which may enroll from 20 to 200 participants in total, will administer the DC-CTL cells 1 to 2 days after the patients have received conventional antitumor therapy.

© 2025 MJH Life Sciences

All rights reserved.